BR0111220A - Conjugados de fármacos de etilenocisteìna (ec) - Google Patents

Conjugados de fármacos de etilenocisteìna (ec)

Info

Publication number
BR0111220A
BR0111220A BR0111220-1A BR0111220A BR0111220A BR 0111220 A BR0111220 A BR 0111220A BR 0111220 A BR0111220 A BR 0111220A BR 0111220 A BR0111220 A BR 0111220A
Authority
BR
Brazil
Prior art keywords
drug conjugates
chelated
ethylenocysteine
specific
tool
Prior art date
Application number
BR0111220-1A
Other languages
English (en)
Other versions
BRPI0111220B8 (pt
BRPI0111220B1 (pt
Inventor
David J Yang
Chun-Wei Liu
Dong-Fang Yu
E Edmund Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/599,152 external-priority patent/US7067111B1/en
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR0111220A publication Critical patent/BR0111220A/pt
Publication of BRPI0111220B1 publication Critical patent/BRPI0111220B1/pt
Publication of BRPI0111220B8 publication Critical patent/BRPI0111220B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"CONJUGADOS DE FáRMACOS DE ETILENODICISTEìNA (EC)". A invenção fornece, num sentido geral, uma nova estratégia de rotulação com emprego de 99Tc quelado com etilenodicisteína (EC). EC é conjugada com uma variedade de ligantes e quelada ao ^ 99m^Tc para uso em um agente de geração de imagem para doenças específicas de tecido. Os conjugados do fármaco da invenção podem também ser usados como uma ferramenta de prognóstico ou como uma ferramenta para entregar compostos terapêuticos a sítios específicos num corpo de mamífero. Estojos para uso na geração de imagem de doenças específicas de tecido são também providos.
BRPI0111220A 2000-06-02 2001-06-01 conjugados de fármacos com etilenodicisteína (ec) BRPI0111220B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58758300A 2000-06-02 2000-06-02
US09/599,152 US7067111B1 (en) 1999-10-25 2000-06-21 Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PCT/US2001/018060 WO2001091807A2 (en) 2000-06-02 2001-06-01 Ethylenedicysteine (ec)-drug conjugates

Publications (3)

Publication Number Publication Date
BR0111220A true BR0111220A (pt) 2003-06-24
BRPI0111220B1 BRPI0111220B1 (pt) 2016-10-11
BRPI0111220B8 BRPI0111220B8 (pt) 2021-07-27

Family

ID=27080078

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111220A BRPI0111220B8 (pt) 2000-06-02 2001-06-01 conjugados de fármacos com etilenodicisteína (ec)

Country Status (15)

Country Link
US (4) US7615208B2 (pt)
EP (2) EP2316494A1 (pt)
JP (3) JP5448284B2 (pt)
KR (1) KR100784120B1 (pt)
CN (1) CN1292798C (pt)
AU (2) AU7521001A (pt)
BR (1) BRPI0111220B8 (pt)
CA (1) CA2410906C (pt)
DK (1) DK1286704T3 (pt)
ES (1) ES2518926T3 (pt)
HU (1) HU230437B1 (pt)
IL (2) IL153218A0 (pt)
NO (1) NO332574B1 (pt)
PL (1) PL212211B1 (pt)
WO (1) WO2001091807A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
EP1381839A4 (en) * 2001-04-03 2005-10-12 Univ Leland Stanford Junior METHOD FOR THE IMAGE OF CELL DEOD IN VIVO
CA2445826C (en) 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
KR20040091076A (ko) * 2002-02-26 2004-10-27 아마토 세이야쿠 가부시키가이샤 리포솜에의 금속착체의 봉입방법
JP4846199B2 (ja) 2002-03-11 2011-12-28 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド テクネチウム−ジビリジン複合体、およびその使用法
US7824661B2 (en) 2002-03-11 2010-11-02 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
DK2260875T3 (da) 2002-05-06 2014-06-30 Endocyte Inc Folatreceptor-targetede billeddannelsesmidler
KR101086690B1 (ko) * 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
CN100381177C (zh) * 2003-01-27 2008-04-16 恩多塞特公司 维生素受体结合递药缀合物
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
KR20070029148A (ko) 2004-02-12 2007-03-13 몰레큘러 인사이트 파마슈티칼스, 인크. 테크네튬- 및 레늄-비스(헤테로아릴) 착체 및 그의 사용방법
WO2005087275A2 (en) * 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
RU2007140391A (ru) * 2005-04-01 2009-05-10 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) Поли(пептид) как хелатор: способы получения и применения
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
WO2008064040A2 (en) * 2006-11-22 2008-05-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
WO2008119036A2 (en) * 2007-03-27 2008-10-02 Radiomedix Inc. Compositions for targeted imaging and therapy
CA2688308A1 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
CN102159253A (zh) * 2008-03-24 2011-08-17 得克萨斯大学体系董事会 心肌病的显像引导的治疗:组合物、制备和用途
CN101721720B (zh) * 2008-10-29 2011-08-24 阮建评 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体
WO2011044377A2 (en) * 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
US20110280770A1 (en) * 2010-05-12 2011-11-17 Jeffrey Lacy Nanogenerator
DK2721045T3 (en) * 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
RS60085B1 (sr) 2012-03-26 2020-05-29 Univ Texas Efikasna sinteza konjugata etilendicisteina i šećera za vizualizaciju i terapiju
US9886546B2 (en) 2012-11-20 2018-02-06 General Electric Company Methods and apparatus to label radiology images
BR112016010927A2 (pt) * 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
EP3334466B1 (en) 2015-08-14 2020-05-13 Endocyte, Inc. Method of imaging with a chelating compound
WO2017090047A1 (en) 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
CN111372940A (zh) * 2017-09-19 2020-07-03 阿尔伯塔大学理事会 生物还原活化的化合物、其前药、放射性药物、组合物及其在包括癌症在内的低氧疾病的多模式治疗控制中的应用
RU2692451C2 (ru) * 2017-10-02 2019-06-24 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ радионуклидной диагностики опухолей головного мозга
WO2019123409A1 (en) 2017-12-21 2019-06-27 University Of The Free State Multinuclear complexes and their preparation
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN112672762B (zh) * 2018-07-26 2025-06-13 普渡研究基金会 用于抗流感化学治疗和免疫治疗的小分子配体靶向药物缀合物
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CN113041366A (zh) * 2021-03-12 2021-06-29 青岛大学附属医院 一种新型肿瘤乏氧正电子显像剂及其制备方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141654A (en) 1977-05-23 1979-02-27 James V. Massey, III Standard for calibrating and/or verifying instrument accuracy
US4279992A (en) 1978-03-13 1981-07-21 Miles Laboratories, Inc. Specific binding assay employing an enzyme-cleavable substrate as label
US4181654A (en) 1978-07-24 1980-01-01 The United States Of America As Represented By The United States Department Of Energy 2,3-Dihydroxybenzoic acid amides of tetraazaalkanes and tetaaza cycloalkanes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5648063A (en) 1981-07-24 1997-07-15 Schering Aktiengesellschaft Sterile composition comprising a chelate complex for magnetic resonance imaging
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5242679A (en) 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
GB8525974D0 (en) 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4789542A (en) 1986-04-29 1988-12-06 The United States Of America As Represented By The United States Department Of Energy Radioiodinated glucose analogues for use as imaging agents
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
IN165717B (pt) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4730968A (en) 1986-09-08 1988-03-15 David Diperstein Self-tapping, self-aligning thread repair insert
US5279811A (en) 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US5164294A (en) 1988-05-17 1992-11-17 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5071965A (en) 1988-07-19 1991-12-10 Mallinckrodt Medical, Inc. Novel tc-99m complexes
US4925650A (en) 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
WO1991016076A1 (en) 1990-04-17 1991-10-31 Mallinckrodt Medical, Inc. Method and kit for preparing technetium-99m complexes
WO1991019516A1 (en) * 1990-06-18 1991-12-26 Mallinckrodt Medical, Inc. Metal-radionuclide complex comprising isonitrile ligands
US5385719A (en) 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
WO1993008839A1 (en) 1991-11-08 1993-05-13 Curators Of The University Of Missouri Multifunctional ligands for potential use in the design of therapeutic or diagnostic radiopharmaceutical imaging agents
US5310536A (en) 1992-02-06 1994-05-10 Mallinckrodt Medical, Inc. Ligands for improving metal chelate formation kinetics
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP1138334A3 (en) 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5496533A (en) * 1992-07-31 1996-03-05 Australian Nuclear Science & Technology Organisation Rhenium complexes
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5951964A (en) 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
JPH07126165A (ja) * 1993-10-29 1995-05-16 Masao Oguro 腫瘍治療剤
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
AU2194695A (en) 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5730968A (en) 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
CA2204254C (en) 1994-11-17 2010-02-16 Stephen Lewis Hart Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US5643883A (en) 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
US5955605A (en) 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
JP3543201B2 (ja) * 1995-10-03 2004-07-14 日本ペイント株式会社 熱硬化性樹脂粒子の製造方法
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JP3963996B2 (ja) * 1996-03-28 2007-08-22 日本メジフィジックス株式会社 糖代謝機能診断剤
US5986074A (en) 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
IT1284046B1 (it) 1996-06-21 1998-05-08 Bracco Spa Processo per la preparazione di tetraazamacrocicli
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
ATE298344T1 (de) 1996-08-27 2005-07-15 Univ Utah Res Found Biokonjugate und verabreichung von bioaktiven substanzen
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US6117551A (en) * 1996-12-18 2000-09-12 Toray Industries, Inc. Carbon fiber prepreg, and a production process thereof
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
EP0879606A1 (en) * 1997-04-25 1998-11-25 Paul Scherrer Institut Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
HUP0001261A3 (en) 1997-04-30 2001-11-28 Univ Washington Seattle Method of imaging cell death in vivo
JP3794517B2 (ja) * 1997-05-08 2006-07-05 日本メジフィジックス株式会社 腫瘍診断剤
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
EP1032668B1 (en) * 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
WO1999039748A1 (en) 1998-02-06 1999-08-12 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
CA2331348C (en) 1998-05-07 2007-07-24 Immunomedics, Inc. Positron emission tomography using gallium-68 chelates
GB9811059D0 (en) 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
WO1999061428A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
IT1302125B1 (it) 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
DE19905094C1 (de) 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
AU3699000A (en) 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US20010041189A1 (en) 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CN101041079A (zh) 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
CA2406852A1 (en) 2000-04-20 2001-11-01 The University Of British Columbia Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy
EP1283874A2 (en) 2000-05-12 2003-02-19 Wolfgang Knecht Novel deoxynucleoside kinase enzyme variants
DE10024874A1 (de) 2000-05-16 2001-11-29 Siemens Ag Polierflüssigkeit und Verfahren zur Strukturierung von Metallen und Metalloxiden
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
AU2001270134B2 (en) 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US6656450B2 (en) 2000-07-17 2003-12-02 California Institute Of Technology, Inc. Macrocyclic magnetic resonance imaging contrast agents
FR2811985A1 (fr) 2000-07-19 2002-01-25 Univ Bretagne Occidentale Procede de synthese de la n1, n3-bis(2-aminoethyl)propane- 1,3-diamine, intermediaires de synthese, produits ainsi obtenus et leur application a la synthese de cyclam
US6440389B1 (en) 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
AU9500201A (en) 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
KR20030051828A (ko) 2000-11-16 2003-06-25 파마시아 앤 업존 컴파니 에스트로겐 의존성 질환의 병용 치료법
WO2002043775A2 (en) 2000-11-20 2002-06-06 GODFREY, Cullen, M. Paramagnetic metal ion-based macrocyclic contrast agents
CA2432792C (en) 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
JP2002241307A (ja) 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030152512A1 (en) 2001-11-13 2003-08-14 Milind Rajopadhye Imaging thrombus with glycoprotein llb/llla antagonists
EP1458416A1 (en) 2001-12-13 2004-09-22 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7121926B2 (en) 2001-12-21 2006-10-17 Micron Technology, Inc. Methods for planarization of group VIII metal-containing surfaces using a fixed abrasive article
EP1776781B1 (en) 2004-08-13 2012-05-23 LG Electronics Inc. Establishment of radio resource control connection in wireless communication system

Also Published As

Publication number Publication date
HUP0300951A3 (en) 2005-11-28
US20070297976A1 (en) 2007-12-27
AU7521001A (en) 2001-12-11
US7615208B2 (en) 2009-11-10
KR20030031905A (ko) 2003-04-23
US8236279B2 (en) 2012-08-07
CA2410906C (en) 2012-10-02
JP2012193199A (ja) 2012-10-11
JP5448284B2 (ja) 2014-03-19
IL153218A0 (en) 2003-07-06
JP2008208138A (ja) 2008-09-11
CA2410906A1 (en) 2001-12-06
EP1286704B1 (en) 2014-07-23
BRPI0111220B8 (pt) 2021-07-27
HUP0300951A2 (hu) 2003-07-28
NO20025729D0 (no) 2002-11-28
IL153218A (en) 2010-02-17
US20100055035A1 (en) 2010-03-04
US20140200329A1 (en) 2014-07-17
DK1286704T3 (da) 2014-09-22
JP2003534388A (ja) 2003-11-18
NO20025729L (no) 2003-01-29
ES2518926T3 (es) 2014-11-05
EP1286704A2 (en) 2003-03-05
WO2001091807A3 (en) 2002-08-29
PL359337A1 (en) 2004-08-23
NO332574B1 (no) 2012-11-05
WO2001091807A2 (en) 2001-12-06
JP5781026B2 (ja) 2015-09-16
BRPI0111220B1 (pt) 2016-10-11
HU230437B1 (hu) 2016-06-28
AU2001275210B2 (en) 2006-09-28
CN1438899A (zh) 2003-08-27
EP2316494A1 (en) 2011-05-04
CN1292798C (zh) 2007-01-03
HK1056682A1 (zh) 2004-02-27
US20130165631A1 (en) 2013-06-27
PL212211B1 (pl) 2012-08-31
KR100784120B1 (ko) 2007-12-12

Similar Documents

Publication Publication Date Title
BR0111220A (pt) Conjugados de fármacos de etilenocisteìna (ec)
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
BR0015194A (pt) Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial
BR9807055A (pt) Composição farmacêutica, uso de um agente fotoquimioterapêutico precursor da protoporfirina junto com um fotossensibilizador de localização de estroma vascular, produto contendo os mesmos, kit para uso em fotoquimioterapia de distúrbios ou anormalidades das superfìcies externa ou interna do corpo, e, processos de tratamento fotoquimioterapêutico de distúrbios ou anormalidades de superfìcies externa ou interna do corpo, e de diagnóstico in vitro de anormalidades ou distúrbios, mediante ensaios de uma amostra de fluidos corporais ou tecidos de um paciente
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
BR0206985A (pt) Anticorpos modificados e métodos de uso
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
SE0001899D0 (sv) New compounds
EP0939627A4 (en) PENTAFLUOROBENZENE SULFAMIDES AND THE LIKE
BR0010478A (pt) Vacina de célula total contendo antìgeno de staphyloccocus aureus
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR9809785A (pt) Composto de ligação de receptor de calcitonina, reagente, agente de formação de imagem cintigráfica, composição, agente radio-terapêutico, complexo, kit para preparar uma preparação radio-farmacêutica, processos para rotular o reagente, para fabricar o reagente, e, uso do reagente
EP0337746A3 (en) Composition for enhancing the biodistribution of antibody for localization in lesions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2001, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/06/2021